Twoja Przychodnia Szczecinskie Centrum Medyczne Sp. z o.o. — Clinical Trial Site

110 Registered trials

45 Currently recruiting

Organisation

Twoja Przychodnia Szczecinskie Centrum Medyczne Sp. z o.o.

Location

Szczecin, Poland

Identifier

ORG-100040198

Address

Ul. Juliusza Slowackiego 19, 71-434, Poland

Departments

-
„Twoja Przychodnia SCM”
#40743: Twoja Przychodnia SCM
#PL10002: Gastrology
40743: Dermatology
5210: Twoja Przychodnia SCM
Dermatologia
Dermatology
Gastroenterology
n.d.
N/A
NA
Not applicable
PL10020:Twoja Przychodnia SCM
PL10022_Twoja Przychodnia SCM
PL10023: Twoja Przychodnia - SCM
Podmiot leczniczy: Twoja Przychodnia
Podmiot leczniczy: Twoja Przychodnia SCM
Site: TWOJA PRZYCHODNIA Szczecińskie Centrum Medyczne/ ul. Juliusza Słowackiego 19, 71-434 Szczecin
TBC
Twoja Przychodnia - SCM
Twoja Przychodnia - Szczecinskie Centrum Medyczne
Twoja Przychodnia – SCM
Twoja Przychodnia – Szczecińskie Centrum Medyczne
Twoja Przychodnia SCM
TWOJA PRZYCHODNIA SCM Poradnia dermatologiczna
Twoja Przychodnia SCM, Poradnia Ginekologiczno-Położnicza
Twoja Przychodnia Szczecinskie Centrum Medyczne
Twoja PrzychodniaSCM

Clinical trials at this site (110)

Search interface

A Study Evaluating BFB759 in Moderate to Severe Hidradenitis Suppurativa Recruiting

2025-522440-41-00 Hidradenitis Suppurativa 4 2026-04-27
A 16-Week Study to Learn About the Study Medicine Called Ritlecitinib in Adults With Long Lasting Painful Red Skin Lumps, Known by the Medic… Recruiting

2025-522705-37-00 HIDRADENITIS SUPPURATIVA 4 2026-04-21
LY4268989 (MORF-057) Co-Administered with Mirikizumab in Adults with Moderately to Severely Active Ulcerative Colitis: A Phase 2 Study Recruiting

2025-522338-30-00 Ulcerative Colitis 4 2026-03-31
An induction study to investigate the efficacy and safety of duvakitug in participants with moderately to severely active Crohn's Disease Recruiting

2025-521036-11-00 Immune system disseases 5 2026-03-23
An induction study to investigate the efficacy and safety of duvakitug in participants with moderately to severely active Ulcerative Colitis Recruiting

2025-521035-37-00 Immune system diseases 5 2026-03-02
ZENITH: Zilebesiran in Patients with Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk … Recruiting

2025-522960-34-00 Established cardiovascular disease 5 2026-02-09
A Study of KT-621 Administered Orally to Participants with Moderate to Severe Atopic Dermatitis (BROADEN2) Recruiting

2025-522370-36-00 Moderate to Severe Atopic Dermatitis 4 2026-02-02
Atacicept in Multiple Glomerular Diseases Recruiting

2024-518465-10-00 Multiple Autoimmune Glomerular Diseases 4 2025-12-12
Study to Evaluate Plozasiran in Adults with Hypertriglyceridemia (SHASTA-10 Study) Recruiting

2024-519712-13-00 Hypertriglyceridemia (HTG) 5 2025-12-08
A Phase 2 trial to investigate efficacy and safety of vipoglanstat in women with endometriosis Recruiting

2025-522452-16-00 Endometriosis related pain 4 2025-12-05
Efficacy and Safety of Icotrokinra in Participants with Moderately to Severely Active Crohn’s Disease Recruiting

2025-521382-27-00 Moderately to Severely Active Crohn's Disease 10 2025-12-04
Efficacy and Safety of Icotrokinra in Adult and Adolescent Participants with Moderately to Severely Active Ulcerative Colitis Recruiting

2025-521381-10-00 Moderately to Severely Active Ulcerative Colitis 5 2025-12-03
A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis Recruiting

2025-521242-26-00 Moderately to Severely Active Ulcerative Colitis 4 2025-11-27
A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN) ( PREVAIL ) Recruiting

2024-519345-30-00 IgA nephropathy 5 2025-11-12
A Phase 3b, Double-Blind, Multicenter, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Children and Adoles… Recruiting

2024-518156-24-00 Atopic Dermatitis 5 2025-11-10
A Study to Assess the Efficacy, Safety, and what the body does to RO7837195 in Participants with Moderately to Severely Active Ulcerative Co… Recruiting

2025-520690-39-00 Moderately to Severely Active Ulcerative Colitis (UC) 4 2025-11-04
A study to evaluate the long-term safety, tolerability, and efficacy of subcutaneous sonelokimab in participants with moderate to severe hid… Recruiting

2025-520564-17-00 Hidradenitis suppurativa (HS) 5 2025-10-16
A study to investigate the effect of AZD6793 in participants with moderate to very severe chronic obstructive pulmonary disease Recruiting

2025-520473-40-00 Moderate to Very Severe Chronic Obstructive Pulmonary D 4 2025-09-29
Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn’s Disease and Obesity or Overweight:… Recruiting

2024-520210-21-00 Crohn’s Disease 5 2025-09-19
A study to evaluate the efficacy and safety of ruxolitinib cream in children (6 to <12 years old) with non-segmental vitiligo Recruiting

2024-513171-41-00 Vitiligo 5 2025-09-11
A Continuation Study of TAK-279 in Adults With Ulcerative Colitis (UC) and Crohn’s Disease (CD) Recruiting

2024-518914-18-00 Moderate to Severely Active Ulcerative Colitis & Modera 4 2025-08-27
A trial to learn how well baxdrostat with dapagliflozin works compared to dapagliflozin on clinical outcomes alone and how safe it is in adu… Recruiting

2023-506460-14-00 Chronic kidney disease (CKD) and hypertension. 5 2025-05-07
A Phase 3, Multicenter, Open-Label Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of TAK-279 in Subjects with Moderate-t… Recruiting

2024-512496-12-00 Moderate to Severe Plaque Psoriasis 5 2025-04-01
Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease ( ENHANCE-CD ) Recruiting

2023-508234-34-00 Crohn's disease 4 2025-01-27